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OBJECTIVES: To understand the current extent of anemia in
HIV/AIDS patients and its impact on health-related quality of
life (HRQL). METHODS: HIV/AIDS patients >18 years of age
were recruited from STD/HIV clinics across the US throughout
2003 to complete self-administered questionnaires. Clinical
status was assessed with questions on medical history and HIV
disease and treatment, while HRQL was quantiﬁed using the SF-
8. RESULTS: In total, 2044 patients were recruited; 498 (24%)
reported that they experienced anemia (as indicated by a health
care provider) as a side effect of medication within the previous
month. Although anemic and non-anemic individuals were
similar in age, gender, HIV viral load, and use of AZT, NRTI
and NNRTI treatment, anemic patients were more likely to be
non-Caucasian, have a lower CD4 count, and more likely to be
on PIs. Similarly, anemic patients were signiﬁcantly more likely
to have anxiety, depression, and cardiovascular comorbidities 
(p < 0.0001). Further, anemic patients had signiﬁcantly lower
scores vs. non-anemic patients on the mental and physical com-
ponent summary scores of the SF-8 (mental: 38.2 + 11.6 anemic
vs. 42.9 + 11.9 non-anemic p < 0.0001; physical: 40.1 + 10.0
anemic vs. 45.5 + 10.4 non-anemic p < 0.0001). There was a sig-
niﬁcantly higher prevalence of great difﬁculty or inability to
perform daily work among the anemic patients (33% anemic vs.
19% non-anemic, p < 0.0001). In a multivariate logistic regres-
sion model controlling for relevant demographic, disease and
treatment characteristics, anemic patients experienced signiﬁ-
cantly lower levels of mental (-4.1 SF-8 MCS score, p < 0.001)
and physical (-4.9 SF-8 PCS score, p < 0.001) well-being than
non-anemic patients. CONCLUSION: Independent of AZT use,
anemia is prevalent in the HIV/AIDS population in the HAART
era. Controlling for relevant confounders, anemia is indepen-
dently associated with a diminished HRQL.
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OBJECTIVES: Prior to use in an international study involving
HIV patients, the original 20-item Symptoms Distress Module
(SDM), underwent linguistic validation in 25 languages. The
original scale was developed in US English by the Adult AIDS
Clinical Trials Group to assess the impact of common HIV-
related symptoms (either due to HIV disease or its treatments).
A rigorous methodology was required to ensure conceptual
equivalence and cultural relevance across different languages.
METHODS: The translation process was conducted by a spe-
cialist in each target country using the following standardized
methodology: 1) two forward translations by professional trans-
lators who were native speakers of the target language and ﬂuent
in English; 2) comparison and reconciliation of the translations
by the specialist in the target country and the translators; 3)
back-translation by a native English speaker; 4) comparison of
source and backward version; 5) review by a clinician; and 
6) comprehension test on ﬁve individuals with HIV/AIDS.
RESULTS: The translation process revealed two major chal-
lenges. First, for items which contain two different terms to
describe one single concept, some languages only have one word
that suitably conveys the concept. Second, the comprehension
tests revealed that in countries where people are less used to com-
pleting questionnaires, the instructions “The questionnaire . . .
should take no more than ﬁve minutes to complete” were per-
ceived as stressful. This required alternative wording. CON-
CLUSION: The 25 language versions of the SDM were estab-
lished according to a rigorous standardized translation method-
ology. The process aims to ensure conceptual equivalence across
language versions to facilitate international comparison and
pooling of data. The linguistic validation process as a whole sup-
ports the integration of international feedback on concepts and
wording during the development of questionnaires.
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OBJECTIVES: First, to investigate comorbidities associated with
Alzheimer’s disease (AD) and second, to report eligibility and the
yearly trend of incidence rate of AD in Medi-Cal from 1995 to
2002. METHODS: A retrospective case-control study was con-
ducted using 20% sample of Medi-Cal administrative claims
data from 1995 to 2002. The cases were patients with a diag-
nosis of AD, and were 1 :10 matched to a cohort without AD
based on age and gender. Eligibility was measured by the number
of eligible months. Relative risk (RR) was calculated to estimate
the risk of AD patients developing a proﬁle of 24 common
comorbidities set forth by AHRQ. RESULTS: In total, 6,494
cases and 64,940 controls were identiﬁed. The average age was
84 and 69% were female. During the eight-year study period,
both groups had around 50 eligible months with no signiﬁcant
difference. Hispanics and other minorities (primarily Asians) had
lower risk of having AD (p < 0.0001). In addition to depression
(RR = 1.67) and psychoses (RR = 2.63), which are the known
comorbidities of AD, peripheral vascular disorder (RR = 1.49)
and other neurological disorders (RR = 1.82) were associated
with the AD diagnosis. Interestingly, AD patients had signiﬁ-
cantly lower risk for many other chronic diseases such as CHF
(RR = 0.82), valvular disease (RR = 0.85), hypertension (RR =
0.84), COPD (RR = 0.85), diabetes (RR = 0.85), renal failure
(RR = 0.86), peptic ulcer (RR = 0.86), cancer (RR = 0.69), and
rheumatoid arthritis (RR = 0.80). The yearly incidence rate for
AD slightly declined from 5.8 per 10,000 person-years in 1995
to 4.8 per 10,000 person-years in 2002. Average annual inci-
dence rate was 5.3 per 10,000 person-years. CONCLUSIONS:
The present study demonstrated that patients with AD had
increased risk of some diseases, yet were less likely to experience
many chronic disorders common to elderly patients.
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OBJECTIVES: To evaluate the cost-effectiveness of donepezil 10
mg per day, rivastigmine 6–12mg per day (high dose), and
rivastigmine 1–4mg per day (low dose) compared with no treat-
ment in the management of mild to moderate Alzheimer’s
Disease in Thailand. METHODS: Using the decision tree analy-
sis, the cost-effectiveness model was developed to compare
donepezil, low dose-rivastigmine and high dose-rivastigmine
with no treatment in patients with mild to moderate Alzheimer’s
Disease. Direct medical costs (i.e., the costs of drugs) and direct
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non-medical costs (i.e., physician visits, hospitalizations, and
special nurses/caregivers) were retrieved from a private hospital
in Thailand. Effectiveness was deﬁned as the improvement of 
the Alzheimer’s disease assessment scale-cognitive subscale
(ADAS-cog) scores. Effectiveness data and probabilities used in
the model were obtained from relevant published studies. Sensi-
tivity analyses were performed to determine the model robust-
ness. RESULTS: The cost-effectiveness analyses shows that
compared with no treatment, incremental cost of high dose-
rivastigmine costs the lowest for patients with Alzheimer’s
Disease to gain one point improvement of ADAS-cog score
[30,162 Baht ($754) per year], whereas the incremental cost of
donepezil was 32,362 ($809) Baht per year and low dose-
rivastigmine costs the highest [77,102 ($1928) Baht per year].
Sensitivity analyses shows that the model is robust. CONCLU-
SION: High dose-rivastigmine and donepezil are more cost-
effective compared with low dose-rivastigmine for patients with
Alzheimer’s Disease in Thailand.
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OBJECTIVE: Quetiapine has been shown to be effective in the
treatment of behavioral and psychological signs of dementia
(BPSD). This analysis evaluates the cost-effectiveness of treating
community-dwelling patients with Alzheimer’s disease (AD) and
BPSD in the US. METHODS: A discrete event simulation was
designed to track the symptoms of BPSD and the resulting inﬂu-
ence on costs, caregiver burden and institutionalization in indi-
viduals under two scenarios: treatment with quetiapine at 200
mg per day, and no treatment. The model is populated using data
from a randomized trial comparing quetiapine to placebo, a lon-
gitudinal cohort study in AD patients, US costing sources, and
the literature. Costs, reported in 2004 US dollars, are examined
from the perspective of a comprehensive health care payer and
society, and include doctor visits, nursing home stays, hospital-
ization, adult day care, home health care, caregiver time and que-
tiapine treatment. In the base case, a one year time horizon is
used. RESULTS: On average, untreated patients spend just over
60% of their time in the community with high levels of BPSD,
while caregivers spend an average of 5.7 hours per day caring
for patients. Per patient costs average $35,642, 77% of which
consists of informal caregiving costs. Quetiapine reduces the time
spent with high BPSD by 24 days, while caregiver time is reduced
by 76 hours per patient. A modest reduction in institutionaliza-
tion (9%) is also predicted. The net effect is an increase in direct
costs of $439 per patient ($6830 per high BPSD year avoided),
but savings of $738 from the societal perspective. A total of 96%
of replications resulted in quetiapine dominating no treatment
from the societal perspective. Results are particularly sensitive to
caregiver time valuation. CONCLUSIONS: Treatment with que-
tiapine has the potential to alleviate caregiver burden and can
lead to considerable savings from the societal perspective.
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OBJECTIVES: To identify changes in management levels and
costs for a cohort of nursing home residents admitted for
Alzheimer’s disease (AD) over a six-year period. METHODS:
Long-term care data from Minnesota for 1995 through 2000
were examined. Nurses from Minnesota’s Quality Assurance and
Review Program evaluate care needs of nursing home residents
annually. Residents are classiﬁed according to dependence level
in each of eight activities of daily living (ADL). This ADL assess-
ment and other factors establish the management level and reim-
bursement rate for care. AD cases were identiﬁed using ICD-9
principal diagnosis codes and personal identiﬁers. Only patients
with AD who were residents throughout the six years were 
analyzed. Nursing home reimbursement rates for 2002 were
obtained from Minnesota’s Department of Human Services. Cost
estimates include nursing and ancillary staff care, and room and
board. Costs are reported in 2002 US$. RESULTS: Of the 2382
assessed patients with AD identiﬁed in 1995, 382 qualiﬁed for
this analysis. Of those, 90% were female and the mean age was
81 years (range: 56–101). Behavior problems were noted in 71%
in 1995 and 2000. In 1995, 25% received an antipsychotic agent
regularly. This rate decreased each year and was 15% by 2000.
The proportion of residents in low and medium dependency
levels decreased from 59% to 16% over six years; whereas, the
high dependency group rose from 41% to 84%. In 2000, sig-
niﬁcantly (p = 0.000) more residents were assessed as physically
and mentally incapable of self-preservation than in 1995. On
average, this increase in care needs resulted in an additional
annual cost of $7273 per resident by the end of the six-year
period and roughly $2.6 million for the cohort. CONCLU-
SIONS: Patients with AD residing in nursing homes continue to
deteriorate over time, resulting in a substantial increase in care
needs and costs.
PNL5
DRUG PERSISTENCY OF TWO CHOLINESTERASE
INHIBITORS—RIVASTIGMINE VERSUS DONEPEZIL AMONG
ELDERLY PATIENTS WITH ALZHEIMER’S DISEASE
Suh DC1,Thomas SK2,Valiyeva E1,Arcona S2,Vo L1
1Rutgers University, Piscataway, NJ, USA; 2Novartis Pharmaceuticals
Co, East Hanover, NJ, USA
OBJECTIVE: To examine the persistency rates and persistency
days of rivastigmine and donepezil in patients with Alzheimer’s
Disease (AD) and to determine predictors of persistency.
METHODS: This retrospective study used MarketScan®
research database during January 1, 1999–December 31, 2002.
The study identiﬁed 229 new users of rivastigmine and 554 new
users of donepezil (i.e., no use of cholinesterase inhibitor (ChEI)
during the 18 month-history period) who were newly diagnosed
with AD between July 1, 2000–June 30, 2001, were at least 65
years old, and had continuous health/prescription insurance.
Patients who reﬁlled their initial ChEI prescription within a per-
missible gap of 60 days after depleting the drug supply from 
the prior prescription were considered to be persistent and the
robustness of the persistency deﬁnition was tested using sensi-
tivity analysis. Kaplan-Meier method and Cox proportional
hazard models were performed to examine the trends of persis-
tency and to identify factors that signiﬁcantly inﬂuenced persis-
tency. RESULTS: During the 1-year follow-up period, 53% of
rivastigmine and donepezil users discontinued or switched their
medications. Discontinuation was more common in donepezil-
users (43%) than in rivastigmine-users (37%), but switching
occurred more frequently in rivastigmine users (16% vs. 10%).
Rivastigmine-users continuously used their medication for an
average of 234 days while donepezil-users for 235 days (p =
0.91). Results were stable with variations in the deﬁnition of con-
